United States· US:0002-1717_1ece6e73-2242-434e-b297-7ccf07a54c1e
Inluriyo
A medicinal product containing imlunestrant, registered in United States by Eli Lilly and Company.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- imlunestrant
- Manufacturer
- Eli Lilly and Company
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 3
- ndc11000217172828 TABLET, FILM COATED in 1 BOTTLE (0002-1717-28)
- ndc11000217175656 TABLET, FILM COATED in 1 BOTTLE (0002-1717-56)
- ndc11000217176156 TABLET, FILM COATED in 1 BOTTLE (0002-1717-61)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Imlunestrant in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaINLURIYOEli Lilly Nederland B.V., Utrecht
- SwitzerlandInluriyo 200 mg, comprimés pelliculésEli Lilly (Suisse) SA
- FranceINLURIYO 200 mg, comprimés pelliculésELI LILLY NEDERLAND BV (PAY-BAS)
- IrelandInluriyo 200 mg film-coated tabletsEli Lilly and Company Limited
- IcelandInluriyoEli Lilly Nederland B.V.*
- NetherlandsInluriyo 200 mg filmomhulde tablettenEli Lilly Nederland B.V.
- PolandInluriyoEli Lilly Nederland B.V.
- SwedenInluriyo 200 mg Filmdragerad tablettEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Inluriyo
- Liechtenstein · Inluriyo
- Norway · Inluriyo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/550af380-51e7-4deb-aa4e-777018a410ef GET /v1/drugs/550af380-51e7-4deb-aa4e-777018a410ef?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": null
},
"productid": "0002-1717_1ece6e73-2242-434e-b297-7ccf07a54c1e",
"productndc": "0002-1717",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "IMLUNESTRANT",
"proprietary_name": "Inluriyo",
"active_ingred_unit": "mg/1",
"application_number": "NDA218881",
"marketing_category": "NDA",
"nonproprietary_name": "imlunestrant",
"start_marketing_date": "20250925",
"active_numerator_strength": "200"
}See everything about imlunestrant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.